All In Biotech

Drug Trial Radar · NCT06895499

Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.

A Phase I/II, Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Efficacy of HB0043 (Bispecific Antibody Targeting IL-17A and IL-36R) in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS).

Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Mar 19, 2025

Primary completion

Jan 30, 2026

Study completion Mar 30, 2026

Sponsor

Sponsor type
Industry
Collaborators
Dermatology Hospital affiliated to Shandong First Medical University
First posted
Mar 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe HS.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • HB0043Drug

    Low dose

  • HB0043Drug

    Medium dose

  • HB0043Drug

    High dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of HB0043 in Patients with Moderate to Severe HSTime frame: From randomization to end of study, assessed up to 24 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermatology Hospital affiliated to Shandong First Medical University

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.